Biomarkers in Drug Discovery - Optimizing Drug Discovery Timeline and Costs

Summary GBI Research, the leading business intelligence provider, has released its latest research, “Biomarkers In Drug Discovery - Optimizing Drug Discovery Timeline and Costs”. The report provides an in-depth analysis of the potential applications of biomarkers in pharmaceutical drug discovery and clinical services. This pharmaceutical and healthcare report suggests investment decisions in biomarker-based drug research by providing information on valid biomarkers, pipelines, case studies, competitive landscape, geographical trends, mergers and acquisitions and market potential. It also provides an analysis on the trends prevailing in the global biomarkers market. In addition to this, the report covers drivers and restrains for the global biomarkers market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope The scope of this report includes: Market Potential and Pipeline Analysis of biomarkers by phase of development, therapeutic class and geography. Market Size and forecast of global biomarkers market and biomarkers drug discovery market from 2000 to 2008, forecast forward to 2015. Analysis of Key geographies including the US (United States), Europe the UK (United Kingdom), France, Germany, Italy and Spain), Australia and Southeast Asia. Investments and Funding Analysis for top companies (Quest Diagnostics, Applied Biosystems, Vermillion, BGMedical, Menarini, Abbott, Roche, Genetech, Affymetrix and Amgen) in the biomarker-based assay development arena. This includes biomarker research on the application and development of novel biomarkers by the top companies and analysis of the competitive factors affecting the global biomarkers market. Qualitative analysis of market drivers, market trends, and challenges. M&A landscape in the biomarkers space segmented by deal value, geography and phase. Reasons to buy The report will improve decision making and will enable you to: Develop business strategies by understanding the trends and developments that are driving the biomarkers-based drug research and development. Design, develop and expand your product development, marketing and sales strategies based on forecast of global biomarkers and biomarkers drug discovery market till 2015 Develop business strategies to exploit biomarkers-based drug discovery market in emerging geographies Identify the key players positioned to take advantage of the emerging market opportunities Exploit M&A opportunities by identifying key market players with the most novel pipeline

Additional Information

GBI Research's new report “Biomarkers in Drug Discovery - Optimizing Drug Discovery Timeline and Cost” provides an in-depth analysis on the potential applications of biomarkers in pharmaceutical drug discovery and clinical services. The report suggests investment decisions in biomarker based drug research by providing information on valid biomarkers, pipelines, case studies, competitive landscape, geographical dominance, mergers and acquisitions and market potential. It also provides an analysis on the trends prevailing in the global biomarkers market. In addition to this, the report also covers market drivers and Restrains for the global biomarkers market.

Increasing Acceptance and Application of Biomarkers in Drug Discover by Pharmaceutical Companies

GBI Research analyzed the increasing application of Biomarkers in drug discovery process and how it facilitates the Pharmaceutical Companies to overcome the challenges posed by conventional drug discovery processes which are time consuming and expensive. High drug attrition rates, safety and efficacy concerns and time consuming methods have encouraged the pharmaceuticals sector to adopt the use of biomarkers in drug discovery process on a large scale. According to the FDA the biomarkers are 10% more efficient in predicting drug failures and hence can save approximately $100m and three to four years in each drug discovery process. Application of the biomarkers in the pharmaceuticals sector can revolutionize the drug discovery process by facilitating treatment decision and introduction of preventive and personalized medicines.

Application of Biomarkers in Each Stage of Drug Discovery

Biomarkers have wide spread applications and are used in several sectors including pharmaceuticals due to their high sensitivity and efficacy. In the pharmaceuticals sector biomarkers have applications in each phase of drug discovery. In drug discovery processes biomarkers are used mainly to monitor the disease progression with the therapy. The reason for their popularity in the pharmaceuticals sector constitutes its ability to detect and monitor disease progression. Biomarkers techniques are non-invasive and robust and have helped them gain popularity over the conventional drug discovery methods. From the early lead and target identification and optimization stages to late stage drug discovery process biomarkers are applicable for target validation, determination of mechanism of action of drug (MOA), drug safety and efficacy and most importantly the therapy response. Biomarkers are applicable in efficiently and accurately studying dosage response during clinical trials stratifying patient population and facilitating faster filings and post marketing surveillance. The efficient integration of biomarkers in each drug discovery stage allows pharmaceutical companies to save time and money on R&D to enhance their pipeline. Pharmaceutical companies wanting to reduce their drug discover cost and time are widely applying novel and validated biomarkers.

Biomarkers in Drug Discovery, Global, Biomarker application in each stage of Drug discovery process, 2008

Source: GBI Research

Wide Spread Use, Flexible FDA Regulations and Integration of ‘Omics’ Drive Biomarkers Market towards Growth

GBI Research has analyzed the factors driving the Biomarkers market towards steady growth. Biomarkers have widespread application in the pharmaceuticals and Disease diagnosis sector. The FDA is somehow flexible in regulating the application of biomarkers in the drug discovery process. This is the key factor contributing to the growth of the biomarkers market. Also the fact that biomarkers application in the drug discovery process involves the integration of the ‘Omics’ technologies like the proteomics, genomics, transcriptomics and others is causing tremendous growth of the biomarkers market. The fact that biomarkers predict accurate safety profile are cost effective and time consuming are those factors open wide scope for the growth of the biomarker application by the pharmaceuticals companies.

Biomarkers Facilitating Quick Turnover of Drugs

Conventional Drug discovery methods are expensive and time consuming. Each drug discovery requires approximately 12-15 years and an expenditure of $800M. According to the FDA biomarkers facility in reducing the over all drug discovery time span to 8-12 years and cut down developmental cost by $100M. Faster and efficient disease progression in each drug discovery stage have caused quick turn over of drugs and helped the pharmaceuticals sector and also the diseased population.

Biomarkers in Drug Discovery, Global, Biomarkers facilitating quick turn over of drugs,2008

Source: GBI Research

Biomarkers Market Expects Significant Growth

GBI Research concludes the advantages of biomarker applications in the drug discovery process by the pharmaceuticals sector and their increased growth. The global biomarkers market is a relatively mature market with approximately $6.3 billion worth revenues in the year 2008. Since 2000 the market has seen extensive growth due to increase in application of biomarkers in molecular diagnostics and clinical services. But its application in drug discovery has been recently realized by the pharmaceutical sector and has a share of 44% in 2008 of the global biomarkers market. By 2015 the market is expected to attain revenues worth $22.2 billion due to expected regulatory and validation procedures for biomarkers to be done by the regulatory bodies. Also rise in awareness and ability to fulfill unmet needs posed by the conventional drug discovery approaches will drive market towards significant growth.